|Day's Range||122.07 - 124.70|
|52 Week Range||87.50 - 139.79|
|PE Ratio (TTM)||-814.08|
|Earnings Date||Aug 7, 2017|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||133.00|
Ligand Pharmaceuticals Incorporated announced today plans to report second quarter 2017 financial results on August 7, 2017. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.
High-margin royalty stocks could be a smart way to play a potentially pricey market.
Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330